MLICM
ELTX icon

Metropolitan Life Insurance Company (MetLife)’s Elicio Therapeutics ELTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-742
Closed -$72.5K – 2798
2021
Q3 		$72.5K Buy
+742
New +$80.2K ﹤0.01% 2689

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ELTX Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Elicio Therapeutics (ELTX) in Q4 2021, closing a stake of 742 shares — an estimated $72.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ELTX in Q3 2021 and held it in 1 quarter. The position peaked at $72.5K in Q3 2021. 53 funds tracked by Wall St. Rank hold ELTX as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Elicio Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 742 Elicio Therapeutics shares in Q4 2021, an estimated $72.5K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Elicio Therapeutics in Q3 2021 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Elicio Therapeutics position peaked at $72.5K in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.